Clinically Guided Warfarin Dose Versus Genotyping In Early Achievement Of Stable Anticoagulant Effect Of Warfarin
Objective To determine efficacy and safety of genotype and clinically guided dosing of warfarin in patients with atrial fibrillation, deep-vein thrombosis, and pulmonary embolism within the first five days after the introduction of therapy.
Saved in:
Published in | Clinical therapeutics Vol. 38; no. 10; p. e10 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Limited
01.10.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Objective To determine efficacy and safety of genotype and clinically guided dosing of warfarin in patients with atrial fibrillation, deep-vein thrombosis, and pulmonary embolism within the first five days after the introduction of therapy. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0149-2918 1879-114X |
DOI: | 10.1016/j.clinthera.2016.07.108 |